

SIMRAN FARMS LIMITED

CIN: L01222MP1984PLC002627

Reg. Office: 1-B, Vikas Rekha Complex, Khatiwala Tank, Indore (M.P.)- 452001

Tel No.: 0731-4255900; Email- compliance@simranfarms.com;

Website: www.simranfarms.com

SFL/BSE/50/2022-23

[Online filing at listing.bseindia.com](http://listing.bseindia.com)

11th Feb, 2023

To,
The Secretary,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Sub: Submission of Standalone & Consolidated Un-audited Financial Results for the Quarter as well as Nine Months ended 31st December, 2022 together with the Limited Review Report as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: SIMRAN FARMS LIMITED (BSE Scrip Code: 519566; ISIN: INE354D01017)

Dear Sir/Madam,

This is in continuation of our letter dated 2nd February, 2023 regarding information of Board Meeting for consideration and approval of Standalone and Consolidated Un-audited Financial Results for the quarter as well as nine months ended 31st December, 2022.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the **Standalone and Consolidated Un-audited Financial Results for the quarter as well as nine months ended 31st December, 2022 together with Limited Review Report** thereon, duly approved by the Board of Directors of the Company at its meeting held today i.e. **Saturday, 11th February, 2023**, at the Registered Office of the Company. ***Copy of Standalone and Consolidated Unaudited Financial Results along with Limited Review Report by the Statutory Auditors of the Company is enclosed with this letter (searchable PDF mode).***

Further, above result shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

These financial results shall also be uploaded on the website of the Company at www.simranfarms.com and on the website of the Stock Exchange at www.bseindia.com. The extract of aforesaid financial results will be published in one Hindi (vernacular) and widely circulated English Newspaper.

Kindly take on record the above said financial results for your reference and record.

Thanking You
Yours faithfully
FOR, SIMRAN FARMS LIMITED

CS Tanu Parmar
CS & Compliance Officer
M. No. A34769
Encl: a/a

SIMRAN FARMS LIMITED

(CIN: L01222MP1984PLC002627)

Regd. Office: 1-B, Vikas Rekha Complex, Khatiwala Tank, Tower Square, Indore (M.P) 452001

Phone: 0731-4255900, Fax: 0731-4255949; Web: www.simranfarms.com, Email: compliance@simranfarms.com

UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(Rs. In Lakhs except EPS)

S. No.	Particulars	STANDALONE						CONSOLIDATED					
		Quarter Ended			Nine Months Ended			Quarter Ended			Nine Months Ended		
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
		Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited	Reviewed	Reviewed	Reviewed	Reviewed	Reviewed	Audited
I	Revenue from Operations	8692.04	8358.62	10609.79	26390.72	30882.59	39370.00	8692.04	8358.62	10609.79	26390.72	30882.59	39370.00
II	Other Income	2.20	0.65	0.88	7.79	6.54	14.78	2.20	0.65	0.88	7.79	6.54	14.78
III	Total Revenue (I+II)	8694.24	8359.27	10610.67	26398.51	30889.13	39384.78	8694.24	8359.27	10610.67	26398.51	30889.13	39384.78
IV	Expenses												
	(a) Consumption of raw materials consumed	6766.59	7314.14	9293.60	21815.69	25258.64	32332.98	6766.59	7314.14	9293.60	21815.69	25258.64	32332.98
	(b) Changes in inventories of finished goods												
	(c) Employees benefits expenses	343.81	371.13	304.43	1050.80	926.06	1309.13	350.72	378.03	304.43	1071.51	926.06	1336.72
	(d) Depreciation	51.31	54.32	52.65	151.86	155.87	208.50	52.96	55.97	54.31	156.82	160.86	215.17
	(e) Finance Cost	46.93	43.18	43.90	155.53	118.01	192.89	46.93	43.34	44.19	155.69	118.30	193.17
	(f) Other expenses	1246.91	1222.39	1245.28	3613.00	3488.39	4622.62	1235.22	1210.31	1232.83	3577.67	3452.3	4574.72
	Total Expenses (IV)	8455.55	9005.16	10939.86	26786.88	29946.97	38666.12	8452.42	9001.79	10929.36	26777.38	29916.16	38652.76
V	Profit/(Loss) from Operations before exceptional /prior period items & tax (III-IV)	238.69	(645.89)	(329.19)	(388.37)	942.16	718.66	241.82	(642.52)	(318.69)	(378.87)	972.97	732.02
VI	Exceptional items / Prior period item	(39.01)	0.00	0.00	(39.01)	0.00	(266.52)	(38.25)	(0.76)	(0.56)	(39.01)	(0.56)	(266.52)
VII	Profit/(Loss) before tax (V-VI)	277.70	(645.89)	(329.19)	(349.36)	942.16	985.18	280.07	(641.76)	(318.13)	(339.86)	973.53	998.54
VIII	Tax expense												
	i) Current tax	11.60	(6.73)	(57.52)	11.60	164.61	123.74	11.92	(5.59)	(54.40)	14.10	173.50	128.38
	ii) Deferred tax	9.60	(123.36)	(13.68)	(109.68)	159.66	(173.13)	8.79	(122.93)	(12.45)	(110.30)	160.40	(157.66)
	iii) MAT credit							0.00		0.00	0.00	0.00	
	Total Tax Expenses (VIII)	21.20	(130.09)	(71.20)	(98.08)	324.27	(49.39)	20.71	(128.52)	(66.85)	(96.20)	333.90	(29.28)
IX	Net Profit/ (Loss) for the period from continuing operations (VII-VIII)	256.50	(515.80)	(257.99)	(251.28)	617.89	1034.57	259.36	(513.24)	(251.28)	(243.66)	639.63	1027.82
X	Profit/ (Loss) for the period from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XII	Net Profit/ (Loss) for the period from discontinuing operations (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit/ (Loss) for the period (IX+XII)	256.50	(515.80)	(257.99)	(251.28)	617.89	1034.57	259.36	(513.24)	(251.28)	(243.66)	639.63	1027.82
XIV	Other comprehensive income												
	Item that will not be reclassified to profit and loss i.e. Remeasurement of defined benefit plans.	0.00	0.00	0.00	0.00	0.00	(1.17)	0.00	0.00	0.00	0.00	0.00	(1.17)
	Less:- Income Tax relating to Item that will not be reclassified to profit and loss i.e. Remeasurement of defined benefit plans.	0.00	0.00	0.00	0.00	0.00	(0.32)	0.00	0.00	0.00	0.00	0.00	(0.32)
	Other Comprehensive Income (XIV)	0.00	0.00	0.00	0.00	0.00	(0.85)	0.00	0.00	0.00	0.00	0.00	(0.85)
XV	Total comprehensive income for the period (XIII+XIV)	256.50	(515.80)	(257.99)	(251.28)	617.89	1033.72	259.36	(513.24)	(251.28)	(243.66)	639.63	1026.97
XVI	Non controlling interest	0.00	0.00	0.00	0.00	0.00	0.00	0.43	0.60	1.41	1.32	4.01	(1.17)
XVII	Total comprehensive income for the period (XV-XVI)	256.50	(515.80)	(257.99)	(251.28)	617.89	1033.72	258.93	(513.84)	(252.69)	(244.98)	635.62	1028.14
XVIII	Paid up Equity Share Capital (Face Value of the Shares of Rs. 10/- each)	379.17	379.17	379.17	379.17	379.17	379.17	379.17	379.17	379.17	379.17	379.17	379.17
XIX	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year						2298.46						2357.43
XX	Earnings Per Share (EPS) (Face Value of Rs. 10/- each)												
	Basic	6.76	(13.60)	(6.80)	(6.63)	16.30	27.29	6.83	(13.55)	(6.66)	(6.46)	16.76	27.14
	Diluted	6.76	(13.60)	(6.80)	(6.63)	16.30	27.29	6.83	(13.55)	(6.66)	(6.46)	16.76	27.14

Handwritten signature

Note:

1. The above unaudited results for the Quarter and Nine Months ended December 31, 2022 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 11/02/2023. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. The above consolidated financial statement includes the financial figures of subsidiary Company i.e. Puregene Biotech Limited.
3. The Company has been primarily engaged in Poultry Breeding & Farming activities only. As such there is no identifiable operating segment, hence there is nothing to disclose under IND AS - 108 'Operating Segment'.
4. The aforesaid unaudited financial results will be uploaded on the Company's website www.simranfarms.com and will also be available on the website of the BSE Limited www.bseindia.com for the benefit of shareholders and investors.
5. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
6. Previous year figures are regrouped/reclassified to conform the current year's presentation.

Place : INDORE

Date : 11th February, 2023




For Simran Farms Limited

H.S. Bhatia
H.S. Bhatia

Managing Director

DIN- 00509426



KHANDELWAL KAKANI & COMPANY

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO
THE BOARD OF DIRECTORS OF
SIMRAN FARMS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **SIMRAN FARMS LIMITED** (the "Company"), for the quarter ended December 31, 2022 and year to date results for the period from 1st April, 2022 to 31st December, 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khandelwal Kakani & Co.
Chartered Accountants
(Firm's Registration No. 001311C)



Santosh Deshmukh
Partner

(Membership No. 071011)

(UDIN:23071011BGWPDN8834)

Place: Indore

Date: February 11th, 2023

Branches : •INDORE •RATLAM •MANDSAUR •BHOPAL •MUMBAI •DELHI

8, Johari Palace, First Floor, 51, M. G. Road, INDORE - 452 001 • Phone : 0731-2518269, 2529539
E-mail : kkc@cakhandelwalkakani.com • info@cakkc.in • Visit us at : www.cakkc.in



KHANDELWAL KAKANI & COMPANY

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO
THE BOARD OF DIRECTORS OF
SIMRAN FARMS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **SIMRAN FARMS LIMITED** (the "Company" or "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), for the quarter ended December 31st, 2022 and year to date results for the period from 1st April, 2022 to 31st December, 2022 ("the statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Name of the Company	CIN No.
1	Simran Farms Limited (Holding Company)	L01222MP1984PLC002627
	Puregene Biotech Limited (Subsidiary Company)	U01222MP1999PLC013303





KHANDELWAL KAKANI & COMPANY

CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below and the certificates of the Appointed Actuaries referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khandelwal Kakani & Co.
Chartered Accountants
(Firm's Registration No. 001311C)



Santosh Deshmukh
Partner

(Membership No. 071011)
(UDIN: 23071011BGWPDO2196)

Place: Indore
Date: February 11th, 2023